Correspondence 0001193125-23-024831 from CalciMedica, Inc. (CALC)
CalciMedica, Inc.
Date: Feb. 6, 2023 · CIK: 0001534133 · Accession: 0001193125-23-024831
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39538
Referenced dates: February 3, 2023
Letter
SEC Response Letter
555 California Street
12th Floor
San Francisco, CA 94104
415.875.2300
Fenwick.com
Julia Forbess
jforbess@fenwick.com | 415.875.2420
February 6, 2023
VIA EDGAR AND OVERNIGHT DELIVERY
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, DC 20549
Attention: Ibolya Ignat
Daniel Gordon
Daniel Crawford
Tim Buchmiller
Re: Graybug Vision, Inc.
Amendment No. 2 to Preliminary Proxy Statement on Schedule 14A
Filed January 31, 2023
File No. 001-39538
Ladies and Gentlemen:
On behalf of Graybug Vision, Inc. (the “Company”), we are concurrently transmitting herewith the Company’s Third Revised Preliminary Proxy Statement on Schedule 14A (the “Third Revised Preliminary Proxy Statement”). In this letter, we respond to the comments of the staff of the Commission (the “Staff”) contained in the Staff’s letter dated February 3, 2023 (the “Letter”) regarding the Company’s Amendment No. 2 to Preliminary Proxy Statement on Schedule 14A as confidentially submitted by the Company to the U.S. Securities and Exchange Commission (the “Commission”) on January 31, 2023. The numbered paragraphs below correspond to the numbered comments in the Letter, and the Staff’s comments are presented in bold italics. Capitalized terms used in this letter but not otherwise defined herein have the meanings set forth in the PRER14A.
U.S. Securities and Exchange Commission
Attention: Ibolya Ignat, Daniel Gordon, Daniel Crawford, Tim Buchmiller
February 6, 2023
Page
Amendment No. 2 to Preliminary Proxy Statement on Schedule 14A filed January 31, 2023
Graybug’s Reasons for the Merger Recommendations of the Graybug Board, page 104
1. We note your response to comment 1. Please revise to disclose how the board, in recommending the business combination, considered the fact that the selected public companies analysis and selected IPOs analysis did not take into consideration the number of product candidates each company was developing, the stage of clinical development of each product candidate for each indication, and the potential addressable market including the expected dosing period of Auxora.
In response to the Staff’s comment, the Company has revised its disclosure on page 105 of the Third Revised Preliminary Proxy Statement.
Graybug Management Liquidation Analysis, page 122
2. We note your response to comment 3 and reissue in part. Given that Piper Sandler assumed a 25% chance of success and that FDA approval is a yes or no decision, it appears Piper Sandler applied a probability of success adjustment that indicated it was more probable that Auxora would not be approved by the FDA and that it was more probable to not generate any revenues. Please revise to disclose how the board took this into consideration in recommending the business combination.
In response to the Staff’s comment, the Company has revised its disclosure on page 121 of the Third Revised Preliminary Proxy Statement.
* * * * * * *
U.S. Securities and Exchange Commission
Attention: Ibolya Ignat, Daniel Gordon, Daniel Crawford, Tim Buchmiller
February 6, 2023
Page
Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (415) 875-2420, or, in her absence, Rob Freedman at (206) 389-4524.
Sincerely,
/s/ Julia Forbess
Show Raw Text
CORRESP 1 filename1.htm SEC Response Letter 555 California Street 12th Floor San Francisco, CA 94104 415.875.2300 Fenwick.com Julia Forbess jforbess@fenwick.com | 415.875.2420 February 6, 2023 VIA EDGAR AND OVERNIGHT DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Ibolya Ignat Daniel Gordon Daniel Crawford Tim Buchmiller Re: Graybug Vision, Inc. Amendment No. 2 to Preliminary Proxy Statement on Schedule 14A Filed January 31, 2023 File No. 001-39538 Ladies and Gentlemen: On behalf of Graybug Vision, Inc. (the “Company”), we are concurrently transmitting herewith the Company’s Third Revised Preliminary Proxy Statement on Schedule 14A (the “Third Revised Preliminary Proxy Statement”). In this letter, we respond to the comments of the staff of the Commission (the “Staff”) contained in the Staff’s letter dated February 3, 2023 (the “Letter”) regarding the Company’s Amendment No. 2 to Preliminary Proxy Statement on Schedule 14A as confidentially submitted by the Company to the U.S. Securities and Exchange Commission (the “Commission”) on January 31, 2023. The numbered paragraphs below correspond to the numbered comments in the Letter, and the Staff’s comments are presented in bold italics. Capitalized terms used in this letter but not otherwise defined herein have the meanings set forth in the PRER14A. U.S. Securities and Exchange Commission Attention: Ibolya Ignat, Daniel Gordon, Daniel Crawford, Tim Buchmiller February 6, 2023 Page 2 Amendment No. 2 to Preliminary Proxy Statement on Schedule 14A filed January 31, 2023 Graybug’s Reasons for the Merger Recommendations of the Graybug Board, page 104 1. We note your response to comment 1. Please revise to disclose how the board, in recommending the business combination, considered the fact that the selected public companies analysis and selected IPOs analysis did not take into consideration the number of product candidates each company was developing, the stage of clinical development of each product candidate for each indication, and the potential addressable market including the expected dosing period of Auxora. In response to the Staff’s comment, the Company has revised its disclosure on page 105 of the Third Revised Preliminary Proxy Statement. Graybug Management Liquidation Analysis, page 122 2. We note your response to comment 3 and reissue in part. Given that Piper Sandler assumed a 25% chance of success and that FDA approval is a yes or no decision, it appears Piper Sandler applied a probability of success adjustment that indicated it was more probable that Auxora would not be approved by the FDA and that it was more probable to not generate any revenues. Please revise to disclose how the board took this into consideration in recommending the business combination. In response to the Staff’s comment, the Company has revised its disclosure on page 121 of the Third Revised Preliminary Proxy Statement. * * * * * * * 2 U.S. Securities and Exchange Commission Attention: Ibolya Ignat, Daniel Gordon, Daniel Crawford, Tim Buchmiller February 6, 2023 Page 3 Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (415) 875-2420, or, in her absence, Rob Freedman at (206) 389-4524. Sincerely, /s/ Julia Forbess Julia Forbess FENWICK & WEST LLP Cc Frederic Guerard, Pharm.D., Chief Executive Officer Robert S. Breuil, Chief Financial Officer Graybug Vision, Inc. Effie Toshav, Esq. Rob Freedman, Esq. Fenwick & West LLP A. Rachel Leheny, Ph.D., Chief Executive Officer CalciMedica, Inc. Carlos Ramirez, Esq. Cooley LLP 3